484 related articles for article (PubMed ID: 16543964)
1. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).
Liu T; Scallan CD; Broze GJ; Patarroyo-White S; Pierce GF; Johnson KW
Thromb Haemost; 2006 Jan; 95(1):68-76. PubMed ID: 16543964
[TBL] [Abstract][Full Text] [Related]
2. Progress in the treatment of bleeding disorders.
Bergman GE
Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
[TBL] [Abstract][Full Text] [Related]
3. Ways to bypass a blocked tenase complex.
Tuddenham EG
Thromb Haemost; 2006 Jan; 95(1):1-2. PubMed ID: 16543953
[No Abstract] [Full Text] [Related]
4. Targeting TFPI for hemophilia treatment.
Peterson JA; Maroney SA; Mast AE
Thromb Res; 2016 May; 141 Suppl 2(Suppl 2):S28-30. PubMed ID: 27207418
[TBL] [Abstract][Full Text] [Related]
5. Studies on the mechanism of action of the aptamer BAX499, an inhibitor of tissue factor pathway inhibitor.
Chang JY; Chantrathammachart P; Monroe DM; Key NS
Thromb Res; 2012 Sep; 130(3):e151-7. PubMed ID: 22658294
[TBL] [Abstract][Full Text] [Related]
6. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
Waters EK; Genga RM; Schwartz MC; Nelson JA; Schaub RG; Olson KA; Kurz JC; McGinness KE
Blood; 2011 May; 117(20):5514-22. PubMed ID: 21389323
[TBL] [Abstract][Full Text] [Related]
7. Multiple congenital coagulopathies co-expressed with Von Willebrand's disease: the experience of Hemophilia Region III Treatment Centers over 25 years and review of the literature.
Asatiani E; Kessler CM;
Haemophilia; 2007 Nov; 13(6):685-96. PubMed ID: 17973844
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma.
Nordfang O; Valentin S; Beck TC; Hedner U
Thromb Haemost; 1991 Oct; 66(4):464-7. PubMed ID: 1796397
[TBL] [Abstract][Full Text] [Related]
9. Localization of the inhibitory site(s) of pentosan polysulphate in blood coagulation.
Wagenvoord R; Hendrix H; Soria C; Hemker HC
Thromb Haemost; 1988 Oct; 60(2):220-5. PubMed ID: 2464199
[TBL] [Abstract][Full Text] [Related]
10. Screening of complex fucoidans from four brown algae species as procoagulant agents.
Zhang Z; Till S; Knappe S; Quinn C; Catarello J; Ray GJ; Scheiflinger F; Szabo CM; Dockal M
Carbohydr Polym; 2015 Jan; 115():677-85. PubMed ID: 25439948
[TBL] [Abstract][Full Text] [Related]
11. Emergency department care for patients with hemophilia and von Willebrand disease.
Singleton T; Kruse-Jarres R; Leissinger C
J Emerg Med; 2010 Aug; 39(2):158-65. PubMed ID: 18757163
[TBL] [Abstract][Full Text] [Related]
12. Buccal mucosa bleeding time is prolonged in canine models of primary hemostatic disorders.
Brooks M; Catalfamo J
Thromb Haemost; 1993 Nov; 70(5):777-80. PubMed ID: 8128434
[TBL] [Abstract][Full Text] [Related]
13. Suppressing protein Z-dependent inhibition of factor Xa improves coagulation in hemophilia A.
Girard TJ; Lasky NM; Grunz K; Broze GJ
J Thromb Haemost; 2019 Jan; 17(1):149-156. PubMed ID: 30451376
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII: maximal benefit?
Nour-Eldin F
Eur J Med; 1992 Apr; 1(1):55-7. PubMed ID: 1341979
[No Abstract] [Full Text] [Related]
15. Structure-activity relationship of the pro- and anticoagulant effects of Fucus vesiculosus fucoidan.
Zhang Z; Till S; Jiang C; Knappe S; Reutterer S; Scheiflinger F; Szabo CM; Dockal M
Thromb Haemost; 2014 Mar; 111(3):429-37. PubMed ID: 24285223
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of hemophilia with immunologic inhibitor of factor VIII by using "activated" coagulant fractions].
Sultan Y; Brouet JC
Nouv Presse Med; 1975 Oct; 4(36):2571-4. PubMed ID: 1081682
[TBL] [Abstract][Full Text] [Related]
17. Drug therapy reviews: clinical use of hemostatic agents.
Lowe GD; Lawson DH
Am J Hosp Pharm; 1978 Apr; 35(4):414-22. PubMed ID: 306196
[TBL] [Abstract][Full Text] [Related]
18. [Capacity of activation of so-called deficient factors in hereditary blood coagulation disorders].
Mingers AM
Fortschr Med; 1976 Oct; 94(30):1723-5. PubMed ID: 1086815
[TBL] [Abstract][Full Text] [Related]
19. A comparison of pentosan polysulphate and heparin. II: Effects of subcutaneous injection.
Fischer AM; Merton RE; Marsh NA; Williams S; Gaffney PJ; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1982 Apr; 47(2):109-13. PubMed ID: 6179183
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein-associated coagulation inhibitor (LACI) is a cofactor for heparin: synergistic anticoagulant action between LACI and sulfated polysaccharides.
Wun TC
Blood; 1992 Jan; 79(2):430-8. PubMed ID: 1346095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
